Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C7R.CD30.CAR-EBVSTs in Relapsed or Refractory CD30-Positive Lymphomas
NCT06176690Phase 1Recruiting
- Sponsor
- Baylor College of Medicine
- Start
- Oct 2025
- Primary completion
- Jul 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of C7R.CD30.CAR-EBVST in CD30-positive lymphoma, sponsored by Baylor College of Medicine. Primary endpoint: Dose Limiting Toxicity at 28 days. Started Oct 2025; status: recruiting.
02
Drugs
C7R.CD30.CAR-EBVST
03
Conditions
CD30-positive lymphoma
Beyond the preview
Go deeper on NCT06176690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06176690.